Pharmaceutical News

RSS

Study sheds new light on the controversy surrounding common osteoarthritis treatment

Injections of hyaluronic acid (HA) are a common treatment of pain in osteoarthritis of the knee - a condition that affects 27 million Americans according to the Centers for Disease Control and Prevention. The injections replace natural HA that has depleted from one's joints, which can cause pain and stiffness due to the lack of lubrication between bones moving against each other.

26 Nov 2015

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years. Researchers from the University and University Hospital Basel have now for the first time successfully combined such an antibody-drug conjugate with a therapy that stimulates the immune system to attack tumor cells.

26 Nov 2015

Researchers encourage more caution in use of ADHD medicine

Authors of new Cochrane Review remain uncertain about effect of widely used medicine on ADHD symptoms, despite large amount of research. Some evidence of increased sleeplessness and loss of appetite leads researchers to encourage more caution in use of methylphenidate.

26 Nov 2015

New drug may show promise against resistant melanomas

A new drug discovered by scientists at Sanford Burnham Prebys Medical Discovery Institute may show promise for treating skin cancers that are resistant or unresponsive to today's leading therapies.

25 Nov 2015

Seqirus announces FDA approval of Fluad for seasonal influenza

Seqirus announced today that the US Food and Drug Administration has approved Fluad (Influenza Vaccine, Adjuvanted) to help protect those aged 65 years and older against seasonal influenza. Fluad is the first adjuvanted seasonal influenza vaccine approved in the United States; it was specifically developed for the adult population aged 65 and older.

25 Nov 2015

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Impax Laboratories, Inc. today announced that the European Commission has granted marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease.

25 Nov 2015

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in testing, was developed and tested in preclinical studies at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Nov 2015

Vitamin D supplements have no effect on frequency and severity of colds in asthma patients

Vitamin D supplements do not reduce the number or severity of colds in asthma patients, according to a new study published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

25 Nov 2015

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.

25 Nov 2015

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announced today that the European Commission has approved Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor (anti-TNF) therapy.

25 Nov 2015

First seasonal influenza vaccine containing adjuvant now approved by FDA

The U.S. Food and Drug Administration today approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older.

25 Nov 2015

Portrazza approved to treat patients with advanced squamous non-small cell lung cancer

The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

24 Nov 2015

T1DM therapeutics market expected to reach $7.1 billion by 2021

Analysis from business intelligence provider GBI Research - Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - states that the global market value for T1DM treatment will rise from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 7.9%.

24 Nov 2015

Impax releases generic version of dutasteride capsules, 0.5 mg

Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.

24 Nov 2015

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo.

24 Nov 2015

New study finds evidence to support meperidine-associated seizure risk

Meperidine, an opioid analgesic commonly used to control shivering in accidental or therapeutic hypothermia, has been linked to increased seizure risk, but a new study finds little published evidence to support this risk.

24 Nov 2015

Green Cross' Biologics License Application for IVIG-SN submitted to FDA

Green Cross Corporation, a South Korean biopharmaceutical company, today announced that it has submitted its Biologics License Application for IVIG-SN (human normal immunoglobulin G for intravenous administration) to the United States Food and Drug Administration.

24 Nov 2015

BioThrax approved to prevent disease after exposure to anthrax spores

The U.S. Food and Drug Administration today approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine's new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure.

24 Nov 2015

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

23 Nov 2015

Leukemia & Lymphoma Society applauds FDA's recent approval of two new multiple myeloma drugs

The Leukemia & Lymphoma Society applauds the FDA's recent approval of two new drugs -- daratumumab and ixazomib -- to treat patients with relapsed multiple myeloma. These therapies are the latest in a growing arsenal to fight this blood cancer that impacts nearly 100,000 patients in the U.S. Advances in treatments for many different types of blood cancers are happening with dizzying speed and these two approvals in just one week are the latest evidence of this phenomenon.

23 Nov 2015

Pharmaceutical News

Study sheds new light on the controversy surrounding common osteoarthritis treatment

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

Researchers encourage more caution in use of ADHD medicine

New drug may show promise against resistant melanomas

Seqirus announces FDA approval of Fluad for seasonal influenza

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

Vitamin D supplements have no effect on frequency and severity of colds in asthma patients

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

First seasonal influenza vaccine containing adjuvant now approved by FDA

Portrazza approved to treat patients with advanced squamous non-small cell lung cancer

T1DM therapeutics market expected to reach $7.1 billion by 2021

Impax releases generic version of dutasteride capsules, 0.5 mg

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

New study finds evidence to support meperidine-associated seizure risk

Green Cross' Biologics License Application for IVIG-SN submitted to FDA

BioThrax approved to prevent disease after exposure to anthrax spores

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Leukemia & Lymphoma Society applauds FDA's recent approval of two new multiple myeloma drugs

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News